PEGylated Pirfenidone

About i-Cordis

i-Cordis is a private, preclinical biotech focused on revolutionizing the treatment of heart failure with preserved ejection fraction (HFpEF) through immunomodulation. The company's lead asset is a PEGylated derivative of pirfenidone, designed to overcome the original drug's limitations (e.g., frequent dosing, CNS side effects) while enhancing cardioprotective effects. With a strong scientific foundation based on the Phase II PIROUETTE trial data for pirfenidone in HFpEF and a world-class team of cardiac immunology experts, i-Cordis is positioning its novel compound as a potential first-in-class therapy for a large, underserved patient population.

Therapeutic Areas

Other Heart Failure with Preserved Ejection Fraction (HFpEF) Drugs